

Supplementary Table 2. Comparison of clinical characteristics according to the presence of END including cardioembolic stroke

	Total (n=1,190)	No END (n=980)	END (n=210)	p
Demographic characteristics				
Sex, male	738 (62.0)	606 (61.8)	132 (62.9)	0.782
Age, years	65.3±3.8	63.4±1.6	70.9±4.4	0.001
Body mass index, kg/m ²	23.8±3.5	23.7±3.3	23.9±3.5	0.835
Risk factors				
Hypertension	768 (64.5)	640 (65.3)	128 (61.0)	0.231
Diabetes mellitus	403 (33.9)	329 (33.6)	74 (35.2)	0.643
Hypercholesterolemia	262 (22.0)	210 (21.4)	52 (24.8)	0.290
Smoking	346 (29.1)	267 (27.2)	79 (37.6)	0.003
Alcohol intake	170 (14.3)	140 (14.3)	30 (14.3)	1.000
Coronary artery disease	223 (18.7)	177 (18.1)	46 (21.9)	0.195
Metabolic syndrome	502 (42.2)	417 (42.6)	85 (40.5)	0.581
Left ventricular hypertrophy	127 (10.7)	100 (10.2)	27 (12.9)	0.258
Prior medication				
Antithrombotic	186 (15.6)	161 (16.4)	25 (11.9)	0.101
Antihypertensive	672 (56.6)	562 (57.3)	110 (52.4)	0.188
Statin	171 (14.4)	149 (15.2)	22 (10.5)	0.076
Antihypertensive treatment before ABI examination	135 (11.3)	112 (11.4)	23 (11.0)	0.843
NIHSS score	4 [1–5]	2 [1–4]	5 [2–8]	0.001
Stroke subtype				0.001
Large-artery atherosclerosis	313 (26.3)	253 (25.8)	60 (28.6)	
Cardioembolism	182 (15.3)	127 (13.0)	55 (26.2)	
Small-vessel occlusion	272 (22.9)	235 (24.0)	37 (17.6)	
Undetermined negative	348 (29.2)	302 (30.8)	46 (21.9)	
Undetermined multiple causes	75 (6.3)	63 (6.4)	12 (5.7)	
Cerebral atherosclerosis				0.001
ECAS	139 (11.7)	110 (11.2)	29 (13.8)	
ICAS	244 (20.5)	181 (18.5)	63 (30.0)	
Both ECAS and ICAS	83 (7.0)	59 (6.0)	24 (11.4)	
HGWMHs	395 (33.2)	316 (32.2)	79 (37.6)	0.133
Thrombolytic therapy	149 (12.5)	87 (8.9)	62 (29.5)	0.001
Blood laboratory findings				
Fasting glucose, mg/dL	116.0±42.2	114.1±41.2	115.3±44.2	0.351
White blood cell count, ×10 ³ /μL	8.4±3.01	8.2±3.1	8.7±2.5	0.049
Hemoglobin, mg/dL	13.7±2.0	13.8±2.0	13.6±2.0	0.147
Platelet count, ×10 ³ /μL	244.4±77.8	242.2±74.2	246.1±77.5	0.523
Total cholesterol, mg/dL	175.3±44.0	176.3±43.7	174.5±44.5	0.431
Triglycerides, mg/dL	118.4±75.2	119.2±75.7	123.2±77.1	0.627
High-density lipoprotein, mg/dL	42.0±11.0	42.3±11.2	41.8±10.9	0.821
Low-density lipoprotein, mg/dL	110.7±38.5	111.4±37.9	109.3±40.3	0.676
ABI parameters				
Arm SBP, mm Hg	150.1±22.1	149.9±22.3	152.1±22.4	0.376
Arm DBP, mm Hg	85.7±12.1	85.8±12.3	85.6±11.9	0.865
baPWV, m/s	19.7±5.1	19.6±4.9	22.5±5.4	0.012
Pulse rate, beats/min	75.4±13.8	72.3±14.9	79.8±12.3	0.121
ABI	1.1±0.1	1.1±0.1	1.0±0.1	0.754
IASBD				
≥5 mm Hg	447 (37.6)	353 (36.0)	94 (44.8)	0.018
≥10 mm Hg	129 (10.8)	94 (9.6)	35 (16.7)	0.003
≥15 mm Hg	22 (1.8)	11 (1.1)	11 (5.2)	0.001
Absolute difference, mm Hg	4.3±4.6	4.0±4.2	5.5±6.4	0.034
IADBD				
≥5 mm Hg	353 (29.7)	263 (26.8)	90 (42.9)	0.001
≥10 mm Hg	75 (6.3)	48 (4.9)	27 (12.9)	0.001
≥15 mm Hg	27 (2.3)	12 (1.2)	15 (7.1)	0.001
Absolute difference, mm Hg	3.5±3.6	3.1±2.9	4.8±5.3	0.023
Both IASBD ≥5 mm Hg and IADBD ≥5 mm Hg	204 (17.1)	147 (15.0)	57 (27.1)	0.001
Both IASBD ≥10 mm Hg and IADBD ≥10 mm Hg	41 (3.4)	26 (2.7)	15 (7.1)	0.001

Data are n (%), mean±standard-deviation, or median [interquartile range] values.

ABI: ankle-brachial index, baPWV: brachial-ankle pulse wave velocity, DBP: diastolic blood pressure, ECAS: extracranial cerebral atherosclerosis, END: early neurological deterioration, HGWMHs: high-grade white-matter hyperintensities, IADBD: interarm diastolic blood pressure difference, IASBD: interarm systolic blood pressure difference, ICAS: intracranial cerebral atherosclerosis, NIHSS: National Institutes of Health Stroke Scale, SBP: systolic blood pressure.